

ABSTRACT OF THE DISCLOSURE

This invention provides the use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) in the treatment or inhibition of
5 hepatic fibrosis and hepatic cirrhosis.